Skip to main content
. 2014 Nov 14;20(42):15564–15579. doi: 10.3748/wjg.v20.i42.15564

Table 3.

Select clinically valuable pancreatic cancer biomarkers

Gene product Target drug Mechanism Ref.
hENT1 Gemcitabine Nucleoside inhibitor, prevents DNA synthesis in cancer cells [59-64]
TS/DPD 5-FU/S-1 Suicide inhibitor of TS, prevents DNA synthesis in cancer cells [65-71]
EGFR Erlotinib Tyrosine kinase inhibitor, prevents EGFR-mediated cell cycle progression and cellular proliferation [72-79]
CA 19-9 N/A N/A [80-88]
SPARC Nab-paclitaxel Disruption of microtubule formation during mitosis [12,89-94]
SMAD4 N/A Tumor suppression, initiation, and metastasis [95-99]

CA 19-9: Carbohydrate antigen 19-9; TS: Thymidylate synthase; hENT1: Human equilibrative nucleoside transporter-1; SPARC: Secreted protein acidic and rich in cysteine; EGFR: Epidermal growth factor receptor.